EDITAS MEDICINE INC.

Immatics and Editas Medicine Enter Strategic Research Collaboration and Licensing Agreement to Combine Gamma-Delta T Cell Adoptive Cell Therapies and Gene Editing for the Treatment of Cancer

07 Jun 2022 07:00:01 By Nasdaq GlobeNewswire

Editas Medicine Reports Inducement Grants to New Chief Executive Officer

06 Jun 2022 16:30:00 By Nasdaq GlobeNewswire

Editas Medicine Presents Data on SLEEK Gene Editing Technology at the American Society of Gene and Cell Therapy Annual Meeting

18 May 2022 06:45:00 By Nasdaq GlobeNewswire

Editas Medicine Receives FDA Orphan Drug Designation for EDIT-301 for the Treatment of Beta Thalassemia

12 May 2022 16:30:00 By Nasdaq GlobeNewswire

Editas Medicine Presents Preclinical Data on EDIT-103 for Rhodopsin-associated Autosomal Dominant Retinitis Pigmentosa at the Association for Research in Vison and Ophthalmology Conference

04 May 2022 13:30:00 By Nasdaq GlobeNewswire

Editas Medicine Announces First Quarter 2022 Results and Business Updates

04 May 2022 06:45:00 By Nasdaq GlobeNewswire

Editas Medicine to Present Pipeline and Platform Data Demonstrating Progress Towards Developing Transformative Gene Editing Medicines at the American Society of Gene and Cell Therapy Annual Meeting

02 May 2022 16:31:07 By Nasdaq GlobeNewswire

Editas Medicine to Host Conference Call Discussing First Quarter 2022 Results and Corporate Update

27 Apr 2022 06:55:00 By Nasdaq GlobeNewswire

Editas Medicine Receives FDA Rare Pediatric Disease Designation for EDIT-301 for the Treatment of Beta Thalassemia

26 Apr 2022 09:00:03 By Nasdaq GlobeNewswire

Editas Medicine Appoints Gilmore O’Neill as Chief Executive Officer

14 Apr 2022 07:30:00 By Nasdaq GlobeNewswire

Editas Medicine Announces Dosing of First Pediatric Patient in the BRILLIANCE Clinical Trial of EDIT-101 for LCA10

11 Apr 2022 09:00:00 By Nasdaq GlobeNewswire

Editas Medicine Reports Engineered iNK Cell Preclinical Data at American Association for Cancer Research Annual Meeting

08 Apr 2022 13:00:00 By Nasdaq GlobeNewswire

Editas Medicine Announces Favorable Decision from U.S. Patent and Trademark Office in CRISPR Patent Interference

28 Feb 2022 16:01:00 By Nasdaq GlobeNewswire

Editas Medicine Announces Fourth Quarter and Full Year 2021 Results and Business Updates

24 Feb 2022 06:30:00 By Nasdaq GlobeNewswire

Editas Medicine to Host Conference Call Discussing Fourth Quarter and Full Year 2021 Results and Corporate Update

16 Feb 2022 06:15:00 By Nasdaq GlobeNewswire

Editas Medicine Reports on Recent Progress and Outlook at J.P. Morgan Healthcare Conference

10 Jan 2022 07:00:02 By Nasdaq GlobeNewswire

Editas Medicine to Present at the 40th Annual J.P. Morgan Healthcare Conference

04 Jan 2022 06:58:00 By Nasdaq GlobeNewswire

Editas Medicine Announces FDA Clearance of Investigational New Drug (IND) Application for EDIT-301 for the Treatment of Transfusion-Dependent Beta Thalassemia

20 Dec 2021 07:00:00 By Nasdaq GlobeNewswire

Editas Medicine Reports Preclinical Data Demonstrating Robust Tumor Reduction and Clearance Using Novel, Engineered iNK Cells at the American Society of Hematology Annual Meeting

12 Dec 2021 18:00:00 By Nasdaq GlobeNewswire

Editas Medicine Presents Preclinical Data on Novel Engineered iPSC-derived NK Cells for the Treatment of Cancer at the Society for Immunotherapy of Cancer 36th Annual Meeting

12 Nov 2021 07:00:02 By Nasdaq GlobeNewswire